OFIX

+ Watchlist + Portfolio

Orthofix Medical Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.48
52-Week Range: $8.85 – $16.99
Market Cap: $404.62M
P/E (TTM): —
EPS (TTM): -1.45
Dividend Yield: —

Advanced Metrics

Price/Book: 0.95
PEG Ratio: 48.83
Return on Equity: -13.91%
Return on Assets: -2.74%
Gross Margin: 71.26%
Operating Margin: -3.26%
Profit Margin: -7.41%
Current Ratio: 2.84
Debt/Equity: 0.61
Total Debt: $261.90M
Free Cash Flow: $4.10M
Revenue Growth: 3.80%
Earnings Growth: —
Enterprise Value: $565.82M

OFIX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$460.71M	$746.64M	$799.49M	$822.31M
Cost of Revenue	$123.54M	$260.37M	$253.61M	$256.30M
Gross Profit	$337.17M	$486.27M	$545.88M	$566.02M
Research & Development	$49.06M	$80.23M	$73.64M	$65.85M
Selling, General & Admin	$308.78M	$530.39M	$532.52M	$554.33M
Operating Expenses	$366.04M	$628.03M	$623.60M	$648.59M
Operating Income	-$28.87M	-$141.76M	-$77.72M	-$82.57M
EBITDA	$15.66M	-$79.49M	-$18.28M	$9.93M
Pretax Income	-$17.71M	-$148.68M	-$123.88M	-$90.81M
Income Tax	$2.04M	$2.72M	$2.12M	$1.38M
Net Income	-$19.75M	-$151.40M	-$126.00M	-$92.19M
Diluted EPS	-0.98	-4.12	-3.30	-2.33
Diluted Shares	20.10M	36.73M	38.10M	39.60M

OFIX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$50.70M	$33.11M	$83.24M	$82.03M
Receivables	$82.86M	$128.10M	$134.71M	$135.75M
Inventory	$100.15M	$222.17M	$189.45M	$172.32M
Current Assets	$255.99M	$420.44M	$433.29M	$416.85M
Total Assets	$458.63M	$925.32M	$893.29M	$850.65M
Current Liabilities	$83.62M	$165.22M	$168.63M	$170.48M
Long-Term Debt	—	$93.11M	$157.01M	$157.39M
Total Debt	$21.53M	$117.07M	$179.63M	$178.44M
Total Liabilities	$121.77M	$326.58M	$390.17M	$400.61M
Retained Earnings	$1.25M	-$150.14M	-$276.14M	-$368.33M
Shareholders' Equity	$336.86M	$598.73M	$503.12M	$450.04M
Working Capital	$172.37M	$255.22M	$264.66M	$246.37M
Net Debt	—	$61.25M	$73.78M	$75.37M

OFIX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.54M	-$45.75M	$25.79M	$33.35M
Capital Expenditure	-$23.16M	-$62.05M	-$34.88M	-$34.63M
Free Cash Flow	-$34.70M	-$107.80M	-$9.09M	-$1.28M
Depreciation & Amortisation	$32.08M	$60.56M	$75.96M	$83.25M
Stock-Based Compensation	$18.44M	$35.71M	$32.45M	$28.69M
Investing Cash Flow	-$24.53M	-$33.13M	-$27.58M	-$34.60M
Financing Cash Flow	-$78.00K	$65.32M	$50.71M	-$786.00K
Net Change in Cash	-$36.15M	-$13.56M	$48.92M	-$2.04M

OFIX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$193.65M	$203.12M	$205.63M	$219.91M	$196.71M
Cost of Revenue	$72.03M	$63.59M	$57.11M	$63.57M	$57.16M
Gross Profit	$121.62M	$139.53M	$148.52M	$156.34M	$139.55M
Research & Development	$19.77M	$15.93M	$14.77M	$15.37M	$15.32M
Selling, General & Admin	$132.98M	$136.49M	$148.10M	$136.75M	$134.91M
Operating Expenses	$171.10M	$156.30M	$166.00M	$155.19M	$153.23M
Operating Income	-$49.48M	-$16.77M	-$17.47M	$1.15M	-$13.69M
EBITDA	-$11.95M	$7.72M	-$3.06M	$17.21M	-$619.00K
Pretax Income	-$52.13M	-$14.22M	-$22.26M	-$2.19M	-$20.83M
Income Tax	$961.00K	-$142.00K	$533.00K	$30.00K	$74.00K
Net Income	-$53.09M	-$14.08M	-$22.80M	-$2.22M	-$20.91M
Diluted EPS	-1.35	-0.36	-0.57	-0.06	-0.52
Diluted Shares	39.20M	39.50M	39.80M	40.00M	40.40M

OFIX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$57.95M	$65.61M	$62.86M	$82.03M	$120.28M
Receivables	$131.87M	$129.56M	$130.81M	$135.75M	$137.78M
Inventory	$174.48M	$172.99M	$174.04M	$172.32M	$177.82M
Current Assets	$390.31M	$395.83M	$394.17M	$416.85M	$461.52M
Total Assets	$823.14M	$837.16M	$832.61M	$850.65M	$886.60M
Current Liabilities	$144.12M	$148.38M	$159.85M	$170.48M	$161.03M
Long-Term Debt	$156.88M	$157.05M	$157.22M	$157.39M	$221.34M
Total Debt	$192.76M	$204.74M	$204.48M	$178.44M	$262.25M
Total Liabilities	$364.85M	$378.81M	$390.12M	$400.61M	$451.42M
Retained Earnings	-$329.24M	-$343.32M	-$366.11M	-$368.33M	-$389.24M
Shareholders' Equity	$458.29M	$458.35M	$442.49M	$450.04M	$435.19M
Working Capital	$246.19M	$247.45M	$234.32M	$246.37M	$300.49M
Net Debt	$98.93M	$91.44M	$94.36M	$75.37M	$101.06M

OFIX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$18.39M	$11.64M	$12.40M	$27.70M	-$17.61M
Capital Expenditure	-$6.74M	-$7.11M	-$9.90M	-$10.88M	-$10.66M
Free Cash Flow	-$25.13M	$4.53M	$2.50M	$16.82M	-$28.27M
Depreciation & Amortisation	$35.68M	$18.00M	$14.52M	$15.05M	$14.55M
Stock-Based Compensation	$6.47M	$7.82M	$7.18M	$7.21M	$6.53M
Investing Cash Flow	-$6.74M	-$7.10M	-$9.89M	-$10.87M	-$10.52M
Financing Cash Flow	-$651.00K	$2.64M	-$5.15M	$2.38M	$63.97M
Net Change in Cash	-$25.78M	$7.18M	-$2.64M	$19.20M	$35.84M

Market Snapshot

About

Global medical device company focused on spine and orthopedic solutions. The company develops and markets surgical implants, biologics, and enabling technologies for spinal disorders and musculoskeletal conditions. Its product portfolio includes bone growth stimulators and regenerative medicine solutions.